Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Complete title: A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Research Study Number 20161740
 
Principal Investigator John Thompson, MD
 
Phase I

Research Study Description

This is a multicenter, open-label, phase 1 study that is being done to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.

The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase.

The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20161740
 
Contact Phase 1 Program, Study Line
 
Telephone 206/288-7551
 
E-mail
 

Keywords: Bladder Cancer; Breast Cancer; Gastrointestinal Cancer; Gynecological Cancer; Head and Neck Cancer; Hematologic Malignancies; Kidney Cancer; Lung Cancer; Lymphoma; Lymphoproliferative Disorders; Melanoma; Lymphoma, Non-Hodgkin (NHL); Sarcoma; Solid Tumors; Mycosis Fungoides/Sezary Syndrome; Neuroendocrine Tumor; Immunoproliferative Disorders; Virus Diseases; Carcinoma, Squamous Cell; Lymphoma, T-Cell; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Connective and Soft Tissue; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Lymphoma, T-Cell, Cutaneous; Neoplasms, Squamous Cell; Immune System Diseases; Mycoses; Immunotherapy; Gastrointestinal Diseases; Polyomavirus Infections; DNA Virus Infections; Tumor Virus Infections; Neoplasms, Human Papillomavirus-Related Malignant

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials